Retrospective analysis of 30 severe autoimmune hemolytic anemia patients treated by whole blood exchange transfusion

Transfusion ◽  
2015 ◽  
Vol 55 (9) ◽  
pp. 2231-2237 ◽  
Author(s):  
Bi-Juan Li ◽  
Xi Yuan ◽  
Yuan-Jun Jiang ◽  
Ning-Li ◽  
Xiang-Wu Shu ◽  
...  
Keyword(s):  
Retrospective Analysis ◽  
Hemolytic Anemia ◽  
Whole Blood ◽  
Autoimmune Hemolytic Anemia ◽  
Exchange Transfusion ◽  
Blood Exchange ◽  
Blood Exchange Transfusion

Thrombotic Thrombocytopenic Purpura: Experience with Whole Blood Exchange Transfusion

1981 ◽  
Vol 7 (01) ◽  
pp. 25-32 ◽  
Author(s):  
Jerome Gottschall ◽  
Anthony Pisciotta ◽  
Joseph Darin ◽  
Clara Hussey ◽  
Richard Aster
Keyword(s):  
Thrombotic Thrombocytopenic Purpura ◽  
Whole Blood ◽  
Exchange Transfusion ◽  
Thrombocytopenic Purpura ◽  
Blood Exchange ◽  
Blood Exchange Transfusion

scholarly journals Whole blood exchange transfusion as a promising treatment of aluminium phosphide poisoning

2018 ◽  
Vol 69 (3) ◽  
pp. 275-277 ◽  
Author(s):  
Nasim Zamani ◽  
Hossein Hassanian-Moghaddam ◽  
Sakine Ebrahimi
Keyword(s):  
Blood Pressure ◽  
Heart Rate ◽  
Whole Blood ◽  
Exchange Transfusion ◽  
Junctional Rhythm ◽  
Aluminium Phosphide ◽  
Blood Exchange ◽  
Blood Exchange Transfusion ◽  
Promising Treatment ◽  
Gross Haematuria

AbstractA 37-year-old male was referred to us about one hour after deliberate ingestion of two 3-gram aluminium phosphide (ALP) tablets. Three hours after admission, his blood pressure dropped to 85/55 mmHg, his heart rate increased to 120 bpm, O2 saturation dropped to 82 %, and the electrocardiogram showed junctional rhythm. We started whole blood exchange, and gross haematuria and jaundice ensued. However, his blood pressure increased, arrhythmia resolved itself, and he was extubated two days after the transfusion was completed. He was sent home seven days after admission completely symptom-free. We believe this treatment may be successfully applied in ALP-poisoned patients.

scholarly journals 1002: USE OF ECMO AND WHOLE BLOOD EXCHANGE TRANSFUSION FOR SEVERE COLCHICINE TOXICITY

2021 ◽  
Vol 50 (1) ◽  
pp. 498-498
Author(s):  
Katelyn Desai ◽  
Anasemon Saad ◽  
Jessica Cheung ◽  
Ami Shah ◽  
Ariel Daube ◽  
...  
Keyword(s):  
Whole Blood ◽  
Exchange Transfusion ◽  
Blood Exchange ◽  
Blood Exchange Transfusion

Fulminant babesiosis treated with clindamycin, quinine,and whole-blood exchange transfusion

Transfusion ◽  
2000 ◽  
Vol 40 (3) ◽  
pp. 375-380 ◽  
Author(s):  
S.E. Dorman ◽  
M.E. Cannon ◽  
S.R. Telford ◽  
K.M. Frank ◽  
W.H. Churchill
Keyword(s):  
Whole Blood ◽  
Exchange Transfusion ◽  
Blood Exchange ◽  
Blood Exchange Transfusion

Serum Endocan, Neuron-Specific Enolase and Ischemia-Modified Albumin Levels in Newborns with Partial Blood Exchange Transfusion

2020 ◽  
Vol 23 ◽  
Author(s):  
Erbu Yarci ◽  
Cuneyt Tayman ◽  
Ufuk Cakir ◽  
Utku Serkant
Keyword(s):  
Exchange Transfusion ◽  
Neuronal Damage ◽  
Neuron Specific Enolase ◽  
Endothelial Damage ◽  
Control Group ◽  
Control Groups ◽  
Term Neonates ◽  
Blood Exchange ◽  
Blood Exchange Transfusion ◽  
And Control

Background:: Hyperviscosity of blood secondary to polycythemia results in increased resistance to blood flow and decrease in delivery of oxygen. Objective:: To evaluate whether serum endocan, NSE and IMA levels can be compared in terms of endothelial injury/ dysfunction and neuronal damage in term neonates with polycythemia who underwent PET. Methods:: 38 symptomatic polycythemic newborns having PET and 38 healthy newborns were included in the study. Blood samples for endocan, NSE and IMA were taken at only postnatal 24 hours of age in the control group and in polycytemia group just before PET, at 24 and 72 hours after PET. Results:: The polycythemia group had higher serum endocan(1073,4 ± 644,8 vs. 378,8 ± 95,9ng/ml; p<0.05), IMA(1,32 ± 0,34 vs.0,601 ± 0,095absorbance unit; p<0.05) and NSE(44,7 ± 4,3 vs. 26,91 ± 7,12μg/l; p<0.05) levels than control group before the PET procedure. At 24 hours after PET, IMA(0,656 ± 0,07 vs. 0,601 ± 0,095absorbance unit; p<0.05) and endocan(510,9 ± 228,6 vs. 378,8 ± 95,9ng/ml; p<0.05) levels were closer to the control group, being still statistically significant higher. NSE levels decreased to control group levels having no difference between the PET and control groups at 24 hours after PET (28,98 ± 6,5 vs. 26,91 ± 7,12μg/l; p>0.05). At 72 hours after PET the polycythemia and control groups did not differ statistically for IMA, endocan and NSE levels (p>0.05). Conclusion:: Serum endocan and IMA levels can be used as a biomarker for endothelial damage / dysfunction and tissue hypoxia in infants with symptomatic polycytemia.

scholarly journals Clinical features and outcomes of autoimmune hemolytic anemia: a retrospective analysis of 32 cases

2011 ◽  
Vol 46 (2) ◽  
pp. 111 ◽  
Author(s):  
Seung-Woo Baek ◽  
Myung-Won Lee ◽  
Hae-Won Ryu ◽  
Kyu-Seop Lee ◽  
Ik-Chan Song ◽  
...  
Keyword(s):  
Retrospective Analysis ◽  
Hemolytic Anemia ◽  
Clinical Features ◽  
Autoimmune Hemolytic Anemia
Sign in / Sign up

Export Citation Format

Share Document